February 1989

Prolongation of Survival of Nude Mice Bearing Human Colon CancerTreatment With Yttrium 90—Labeled Anti—Carcinoembryonic Antigen Antibody

Author Affiliations

From the Departments of General Oncologic Surgery (Drs Hyams, B. G. Beatty, and J. D. Beatty) and Anatomic Pathology (Dr Esteban), City of Hope National Medical Center, Duarte, Calif, and Hybritech Inc, San Diego (Mr Wanek).

Arch Surg. 1989;124(2):175-179. doi:10.1001/archsurg.1989.01410020045007

• Nude mice bearing diffuse intraperitoneal carcinomatosis of the human colon cancer cell line LS174T were treated with an anti–carcinoembryonic antigen monoclonal antibody (MAB) that was labeled with yttrium 90 (90Y-ZCE025). Control animals were either untreated or treated with nonspecific99Y-MAB (90Y-96.5c). The median survival (MS) for untreated animals was 26 days. The MS for specific and nonspecific therapy that consisted of 120 μCi of90Y-MAB was 69 and 34 days, respectively. No significant improvement in the MS was observed with a second 120-μCi administration of90Y-MAB given two weeks later. A decreased MS was observed with 80 μCi of90Y-MAB given every four days for three cycles. In each category, specific therapy had a significant advantage over nonspecific therapy in increased effectiveness and decreased toxicity. The90Y-ZCE025 therapy gave an increased life span of almost 200%. The therapeutic effects with different dosing regimens have important implications for treatment planning.

(Arch Surg 1989;124:175-179)